Beta Drugs Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 3/6
Beta Drugs has been growing earnings at an average annual rate of 32.3%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 28.4% per year. Beta Drugs's return on equity is 23.2%, and it has net margins of 12.3%.
Anahtar bilgiler
32.3%
Kazanç büyüme oranı
31.5%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 17.5% |
Gelir büyüme oranı | 28.4% |
Özkaynak getirisi | 23.2% |
Net Marj | 12.3% |
Son Kazanç Güncellemesi | 31 Mar 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Aug 30Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%
Aug 30Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20Gelir ve Gider Dağılımı
Beta Drugs nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
31 Mar 24 | 2,957 | 364 | 277 | 0 |
31 Dec 23 | 2,759 | 356 | 266 | 0 |
30 Sep 23 | 2,560 | 348 | 254 | 0 |
30 Jun 23 | 2,416 | 327 | 249 | 0 |
31 Mar 23 | 2,271 | 307 | 243 | 0 |
31 Dec 22 | 2,176 | 298 | 226 | 0 |
30 Sep 22 | 2,081 | 289 | 210 | 0 |
30 Jun 22 | 1,960 | 269 | 190 | 0 |
31 Mar 22 | 1,838 | 248 | 170 | 0 |
31 Dec 21 | 1,683 | 216 | 156 | 0 |
30 Sep 21 | 1,528 | 183 | 143 | 0 |
30 Jun 21 | 1,345 | 150 | 132 | 0 |
31 Mar 21 | 1,161 | 117 | 121 | 0 |
31 Dec 20 | 1,058 | 106 | 119 | 0 |
30 Sep 20 | 956 | 95 | 103 | 0 |
30 Jun 20 | 932 | 94 | 99 | 0 |
31 Mar 20 | 908 | 94 | 110 | 0 |
30 Sep 19 | 832 | 97 | 89 | 0 |
30 Jun 19 | 746 | 89 | 76 | 0 |
31 Mar 19 | 659 | 80 | 64 | 0 |
31 Mar 18 | 506 | 68 | 30 | 0 |
31 Mar 17 | 417 | 43 | 53 | 0 |
31 Mar 16 | 264 | 11 | 32 | 0 |
31 Mar 15 | 3 | -1 | 1 | 0 |
31 Mar 14 | 14 | 0 | 2 | 0 |
Kaliteli Kazançlar: BETA has high quality earnings.
Büyüyen Kar Marjı: BETA's current net profit margins (12.3%) are lower than last year (13.5%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: BETA's earnings have grown significantly by 32.3% per year over the past 5 years.
Büyüme Hızlandırma: BETA's earnings growth over the past year (18.6%) is below its 5-year average (32.3% per year).
Kazançlar vs. Sektör: BETA earnings growth over the past year (18.6%) did not outperform the Pharmaceuticals industry 19.1%.
Özkaynak Getirisi
Yüksek ROE: BETA's Return on Equity (23.2%) is considered high.